Dark

LIFE
Ethos Technologies Inc. Class A Common Stock
stock NASDAQ

At Close

Apr 2, 2026 3:59:53 PM EDT

11.90USD+6.631%(+0.74)468,096

0.00Bid 0.00Ask 0.00Spread

Pre-market

Apr 2, 2026 8:24:30 AM EDT

11.55USD+3.495%(+0.39)9,400

After-hours

Apr 1, 2026 4:13:30 PM EDT

11.13USD-0.269%(-0.03)0

OverviewHistoricalExchangesShortsNews

Jan 13, 2022

11:47AM EST aTyr Pharma Announces 'efzofitimod' As Nonproprietary Name For ATYR1923 Benzinga

08:03AM EST aTyr Pharma Advances Development of Lead Therapeutic GlobeNewswire Inc

Jan 6, 2022

08:00AM EST aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for GlobeNewswire Inc

Jan 4, 2022

08:03AM EST aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 10 13, 2022. GlobeNewswire Inc

Dec 24, 2021

08:02AM EST aTyr Pharma Appoints Danielle Campbell as Vice President of Human GlobeNewswire Inc

Dec 10, 2021

08:00AM EST aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a presentation at the Antibody Engineering & Therapeutics Conference which is being held December 12 16, 2021 in San Diego, CA, and virtually. GlobeNewswire Inc

Nov 30, 2021

04:47PM EST aTyr Pharma And FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement For aTyr's Lead Therapeutic Candidate ATYR1923 Benzinga

08:00AM EST aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce GlobeNewswire Inc

Nov 12, 2021

08:00AM EST aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming virtual investor conferences in November. GlobeNewswire Inc

Nov 11, 2021

12:09PM EST What 6 Analyst Ratings Have To Say About aTyr Pharma Benzinga

06:13AM EST HC Wainwright & Co. Maintains Buy on aTyr Pharma, Lowers Price Target to $11 Benzinga

Nov 10, 2021

04:00PM EST Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. GlobeNewswire Inc

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 9, 2021

11:46AM EST aTyr Pharma Presents Research Demonstrating Effects Of Novel NRP2-Targeting Antibody, ATYR2810, On Tumor Associated Macrophages At The Society For Immunotherapy Of Cancer Annual Meeting Benzinga

08:05AM EST Findings provide key insights into ATYR2810s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. GlobeNewswire Inc

Nov 3, 2021

08:00AM EDT aTyr Pharma to Webcast Conference Call Reporting Third Quarter GlobeNewswire Inc

Nov 2, 2021

09:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. GlobeNewswire Inc

Oct 12, 2021

12:29PM EDT Where aTyr Pharma Stands With Analysts Benzinga

10:48AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 Benzinga

06:39AM EDT RBC Capital Initiates Coverage On aTyr Pharma with Outperform Rating, Announces Price Target of $22 Benzinga

Oct 11, 2021

08:00AM EDT aTyr Pharma to Participate in Piper Sandler Investor Lung Day GlobeNewswire Inc

Oct 6, 2021

08:00AM EDT aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as GlobeNewswire Inc

Oct 1, 2021

08:01AM EDT aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held November 10 14, 2021 in Washington, DC, and virtually. GlobeNewswire Inc

Sep 21, 2021

10:33AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021 Benzinga

05:25AM EDT Piper Sandler Initiates Coverage On aTyr Pharma with Overweight Rating, Announces Price Target of $19 Benzinga

Sep 20, 2021

04:07PM EDT aTyr Pharma Announces Closing of $86.3 Million Public Offering GlobeNewswire Inc

Sep 17, 2021

03:04PM EDT aTyr Pharma 13G Filing From Ikarian Capital Shows Raised Stake In Co. From 300K Shares ~889K Shares, Or 5.3% Stake Benzinga

01:00PM EDT What US Stocks Are The Largest Gainers In 2021? Benzinga

Sep 16, 2021

04:02PM EDT aTyr Pharma To Present At The Oppenheimer Fall Healthcare Life Sciences And MedTech Summit On Wednesday, September 22, 2021, At 3:45 p.m. ET. Benzinga

04:01PM EDT aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life GlobeNewswire Inc

08:03AM EDT aTyr Pharma Prices 9,375,000 Share Common Stock Offering At $8/Share Benzinga

08:00AM EDT aTyr Pharma Announces Pricing of $75 Million Public Offering of GlobeNewswire Inc

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

06:36AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.20 A.M. EDT). RTTNews

Sep 15, 2021

04:03PM EDT aTyr Pharma Announces Common Stock Offering; Size Not Disclosed Benzinga

04:01PM EDT aTyr Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

08:57AM EDT Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Sept. 15, 2021: WKHS, LIFE, LMFA, TVAC, RNWK Benzinga

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 14, 2021

12:27PM EDT Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide Benzinga

12:05PM EDT Why aTyr Pharma Shares Are Continuing To Surge Higher Today Benzinga

10:13AM EDT Shares of aTyr Pharma Inc. (LIFE) continued its rally on Tuesday, gaining nearly 30% in the morning trade, on top of the 50% increase recorded on Monday's trading. RTTNews

10:11AM EDT Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August Benzinga

08:56AM EDT Roth Capital Maintains Buy on aTyr Pharma, Raises Price Target to $21 Benzinga

08:45AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

07:36AM EDT Oppenheimer Maintains Outperform on aTyr Pharma, Raises Price Target to $20 Benzinga

Sep 13, 2021

02:40PM EDT Mid-Afternoon Market Update: Dow Rises Over 100 Points; Itamar Medical Shares Spike Higher Benzinga

12:46PM EDT Shares of aTyr Pharma, Inc. (LIFE) are gaining nearly 40% on Monday after the clinical-stage biotherapeutics company and its Hong Kong Subsidiary, Pangu BioPharma, announced positive data from a phase 1b/2a clinical trial demonstrating consistent dose response of ATYR1923 in pulmonary sarcoidosis. RTTNews

12:17PM EDT Mid-Day Market Update: Crude Oil Up 1%; MiMedx Group Shares Plummet Benzinga

09:55AM EDT HC Wainwright & Co. Maintains Buy on aTyr Pharma, Raises Price Target to $18 Benzinga

07:36AM EDT aTyr Pharma Announces Phase 1b/2a Clinical Trial Of ATYR1923 In Pulmonary Sarcoidosis Met Primary Endpoint Benzinga

07:30AM EDT aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical GlobeNewswire Inc

Aug 11, 2021

05:08PM EDT ATyr Pharma Inc Files For Mixed Shelf Of Up To $75M Benzinga

Aug 10, 2021

04:29PM EDT aTyr Pharma: Q2 Earnings Insights Benzinga

04:00PM EDT aTyr Pharma Q2 EPS $(0.64) Misses $(0.51) Estimate Benzinga

04:00PM EDT Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. GlobeNewswire Inc

08:03AM EDT aTyr Pharma Reports Expansion Of Its Research Collab With Ohio State University Benzinga

08:00AM EDT Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. GlobeNewswire Inc

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

08:21AM EDT aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress Benzinga

08:00AM EDT aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for GlobeNewswire Inc

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 3, 2021

08:49AM EDT aTyr Pharma Granted U.S. Patent Titled 'Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities' Benzinga

08:00AM EDT aTyr Pharma to Webcast Conference Call Reporting Second Quarter GlobeNewswire Inc

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

04:12PM EDT aTyr Pharma Announced It Has Been Granted A U.S. Patent For The Use Of Histidyl-RNA Synthetase Fc Fusion Proteins For Reducing Inflammatory Response In The Lung Benzinga

Jul 27, 2021

03:18PM EDT aTyr Pharma Granted U.S. Patent Titled 'Histidyl-tRNA synthetase-Fc conjugates' Benzinga

Jul 21, 2021

10:08AM EDT ATyr Pharma Granted EU Patent Titled 'DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ALANYL TRNA SYNTHETASES' Benzinga

Jul 8, 2021

08:14AM EDT aTyr Pharma Reports Last Patient Visit In Phase 1b/2a Trial OF ATYR1923 In Patients With Pulmonary Sarcoidosis Benzinga

Jun 23, 2021

08:00AM EDT Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic. GlobeNewswire Inc

Jun 10, 2021

04:32PM EDT aTyr Pharma Highlights Presentation Of Second Anti-NRP2 Antibody Of Antibody Engineering & Therapeutics Europe Virtual Benzinga

04:30PM EDT Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. GlobeNewswire Inc

Jun 3, 2021

10:16AM EDT aTyr Pharma Files US Patent & Trademark Office Abstract For Co.'s 'COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES' Benzinga

May 28, 2021

12:25PM EDT aTyr Pharma Shares Spikes to High; Traders Circulate TipRanks Report 'aTyr Pharma: A Penny Stock With Triple-Digit Upside' Benzinga

May 25, 2021

08:00AM EDT aTyr Pharma Strengthens Board of Directors with Appointment of Dr. GlobeNewswire Inc

May 20, 2021

08:59AM EDT ATyr Pharma Director Purchases 50,000 Shares At Avg. Price Of $3.98; CEO Purchases 10,000 Shares At Avg. Price $4.01 Benzinga

May 19, 2021

08:05AM EDT aTyr Pharma Highlights Presentation Preclinical Research Highlighting 'Mechanistic Insights Into Tumor Inhibitory Effects Of ATYR2810' Benzinga

08:00AM EDT aTyr Pharma Presents Preclinical Research Highlighting Mechanistic GlobeNewswire Inc

May 18, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 Benzinga

08:01AM EDT JonesTrading Initiates Coverage On aTyr Pharma with Buy Rating, Announces Price Target of $15 Benzinga

May 13, 2021

04:32PM EDT aTyr Pharma Q1 EPS $(0.51) Misses $(0.34) Estimate Benzinga

04:05PM EDT Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. GlobeNewswire Inc

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 12, 2021

08:11AM EDT aTyr Pharma Reports Its Hong Kong Subsidiary, Pangu BioPharma, Achieved Milestones Set For First Year Of $750K Grant Received From Hong Kong Gov't. Benzinga

08:00AM EDT aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve GlobeNewswire Inc

May 11, 2021

08:00AM EDT aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice GlobeNewswire Inc

May 6, 2021

08:00AM EDT aTyr Pharma to Webcast Conference Call Reporting First Quarter GlobeNewswire Inc

Apr 20, 2021

08:00AM EDT aTyr Pharma and Foundation for Sarcoidosis Research Announce Town GlobeNewswire Inc

Apr 14, 2021

09:42AM EDT aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810 Benzinga

08:06AM EDT aTyr Pharma And Lonza Announce Manufacturing Agreement For aTyr's Anti-NRP2 Antibody ATYR2810; Financial Terms Not Disclosed Benzinga

08:00AM EDT aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the manufacture of ATYR2810, aTyrs monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer. GlobeNewswire Inc

Apr 9, 2021

08:02AM EDT aTyr Pharma To Present Preclinical ATYR2810 Data At 2021 American Association For Cancer Research Annual Meeting Apr. 10 Benzinga

08:00AM EDT Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. GlobeNewswire Inc

Apr 8, 2021

08:00AM EDT aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis GlobeNewswire Inc

Mar 25, 2021

02:45PM EDT Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference Benzinga

Mar 24, 2021

01:41PM EDT From BZ Biotech Conference: aTyr Pharma's President, CEO And Director Dr. Sanjay Shukla Concludes Segment Benzinga

01:36PM EDT From BZ Biotech Conference: aTyr Pharma's President, CEO And Director Dr. Sanjay Shukla Highlights Future Phase 1b, 2a Pulmonary Sarcoidosis Trial Benzinga

01:33PM EDT From BZ Biotech Conference: aTyr Pharma's President, CEO And Director Dr. Sanjay Shukla Says All Fibrosis Roads Lead To Inflammation, Says Co.'s Drugs Have Great Opportunity To Treat Fibrotic Patients Benzinga

01:28PM EDT From BZ Biotech Conference: aTyr Pharma's President, CEO And Director Dr. Sanjay Shukla Highlights Novel Mechanism To Treat Inflammation Benzinga

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

07:04AM EDT Oppenheimer Maintains Outperform on aTyr Pharma, Raises Price Target to $14 Benzinga

Mar 23, 2021

07:12PM EDT Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021 Benzinga

04:46PM EDT aTyr Pharma: Q4 Earnings Insights Benzinga

04:13PM EDT aTyr Pharma Q4 EPS $(0.47) Beats $(0.82) Estimate, Sales $2.05M Beat $130.00K Estimate Benzinga

04:05PM EDT Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter. GlobeNewswire Inc

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

04:26AM EDT Earnings Scheduled For March 23, 2021 Benzinga

Mar 16, 2021

12:06PM EDT Roth Capital Maintains Buy on aTyr Pharma, Raises Price Target to $20 Benzinga

11:49AM EDT Roth Capital Raises Price Target On aTyr Pharma From $16 To $20, Maintains Buy Benzinga

08:00AM EDT aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter GlobeNewswire Inc

Mar 15, 2021

08:07AM EDT aTyr Pharma Announces Data From Phase 2 Clinical Trial Of ATYR1923 In COVID-19 Patients With Severe Respiratory Complications; Says ATYR1923 'reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs' Benzinga

08:00AM EDT Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. GlobeNewswire Inc

Mar 11, 2021

08:02AM EST aTyr Pharma Announces Poster Presentations At Upcoming American Association For Cancer Research Annual Meeting Apr. 10-15 And May 17-21 Benzinga

08:00AM EST aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10 15 and May 17 21. GlobeNewswire Inc

Mar 10, 2021

08:00AM EST Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as GlobeNewswire Inc

Feb 25, 2021

Feb 16, 2021

11:27AM EST Viking Global Investors Reports In 13G Filing An 8.3% Stake In ATyr Pharma; Raised Stake By ~90K Shares Benzinga

Feb 11, 2021

10:34AM EST aTyr Pharma Gains On New Programs From tRNA Synthetase Platform For Cancer Targets Benzinga

08:00AM EST Advancement of selected AARS and DARS fragments primarily targeting cancer GlobeNewswire Inc

Feb 9, 2021

04:45PM EST aTyr Filing Shows Registration For $2.991M Common Stock Shelf Offering Benzinga

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

08:00AM EST aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Digital Conference, which is being held February 16 18, 2021. GlobeNewswire Inc

Jan 25, 2021

08:05AM EST aTyr Pharma To Present A Poster On NRP2 And Participate In Q&A Session At Virtual Keystone Symposia: Tumor Metabolism and the Microenvironment Jan. 27 Benzinga

08:00AM EST Poster highlights NRP2 expression on immune cells in the tumor microenvironment. GlobeNewswire Inc

Jan 22, 2021

08:03AM EST aTyr Pharma Will Present Poster Highlighting Research Approach For Identifying Receptor Targets For Extracellular tRAN Synthetases Benzinga

08:00AM EST Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. GlobeNewswire Inc

Jan 14, 2021

08:07AM EST aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan Benzinga

08:00AM EST aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. GlobeNewswire Inc

Jan 7, 2021

07:00AM EST aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11-14, 2021. GlobeNewswire Inc

Jan 5, 2021

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

Jan 4, 2021

04:15PM EST ATyr Pharma Announces Positive Topline Results From Phase 2 Clinical Trial Of ATYR1923 In COVID-19 Patients With Severe Respiratory Complications; Says Study Met Primary Safety Endpoint Benzinga

04:15PM EST Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. GlobeNewswire Inc

Dec 21, 2020

07:19AM EST ATyr Pharma Completes Enrollment In Phase 1b/2a Clinical Trial Of ATYR1923 In Pulmonary Sarcoidosis; Sees Data In Q3 RTTNews

07:17AM EST aTyr Pharma Completes Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis, Expects to Report Data in Q3 2021 Benzinga

07:00AM EST aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a GlobeNewswire Inc

Dec 1, 2020

12:40PM EST 'Two papers recently published in @ScienceMagazine note that the SARS-CoV-2 virus is able to enter cells via neuropilin receptors, including neuropilin-2 (NRP2), the target receptor of ATYR1923' -Tweet From aTyr Pharma Benzinga

Nov 12, 2020

04:23PM EST aTyr Pharma Q3 EPS $(0.68) Beats $(0.74) Estimate, Sales $148.00K Beat $100.00K Estimate Benzinga

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 11, 2020

02:11PM EST aTyr Pharma Tweets; We are excited to be published in the mAbs Journal with co-author @AbCelleraBio on our novel approaches that facilitate rapid engineering of desirable properties into discovered antibodies. Benzinga

07:00AM EST aTyr Pharma Announces Publication in the Journal mAbs GlobeNewswire Inc

Nov 10, 2020

07:00AM EST Discovery advances the understanding of extracellular tRNA synthetase pathways. GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

07:00AM EST aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results and provide a corporate update after the market close on Thursday, November 12, 2020. GlobeNewswire Inc

Oct 29, 2020

07:56AM EDT aTyr Pharma Announces Research Collaboration with Medical University of South Carolina Benzinga

07:00AM EDT Collaboration with leading expert Dr. Robert Gemmill will support the companys neuropilin-2 (NRP2) antibody program in oncology. GlobeNewswire Inc

Oct 27, 2020

07:00AM EDT aTyr Pharma to Participate in ROTH Capital Partners Webinar on GlobeNewswire Inc

Oct 26, 2020

07:01AM EDT aTyr Pharma Announces Completion Of Enrollment In Phase 2 Clinical Trial Of ATYR1923 In COVID-19 Patients With Severe Respiratory Complications Benzinga

07:00AM EDT aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical GlobeNewswire Inc

Oct 7, 2020

08:00AM EDT aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor events in October. GlobeNewswire Inc

Sep 21, 2020

07:13AM EDT A Peek Into The Markets: US Stock Futures Plunge; Trump Gives 'Blessing' To TikTok-Oracle-Walmart Deal Benzinga

06:04AM EDT A Peek Into The Markets: US Stock Futures Plunge; Trump Gives "Blessing" to TikTok-Oracle-Walmart Deal Benzinga

Sep 18, 2020

04:31PM EDT Atyr Pharma Files For Sale Of Up To 3M Shares Of Its Common Stock By Aspire Capital Fund Benzinga

Sep 15, 2020

07:05AM EDT aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan Benzinga

07:00AM EDT aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. GlobeNewswire Inc

Sep 14, 2020

08:35AM EDT Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com GlobeNewswire Inc

08:15AM EDT aTyr Pharma Announces $20M Stock Purchase Agreement From Aspire Capital; Set To Take Place Over Period Of Up To 30 Months Benzinga

08:03AM EDT Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. GlobeNewswire Inc

Sep 9, 2020

07:00AM EDT aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in September. GlobeNewswire Inc

Sep 8, 2020

12:08PM EDT 2 Conferences Are Going Virtual This Month One On Cannabis And Another Life Sciences Benzinga

Sep 2, 2020

07:00AM EDT aTyr Pharma to Present at Life Sciences Investor Forum on GlobeNewswire Inc

Aug 17, 2020

07:10AM EDT HC Wainwright & Co. Upgrades aTyr Pharma to Buy, Announces $13 Price Target Benzinga

Aug 13, 2020

04:01PM EDT aTyr Pharma Q2 EPS $(0.69) Beats $(0.73) Estimate, Sales $189.00K Up From $94.00K YoY Benzinga

04:00PM EDT aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update. GlobeNewswire Inc

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

04:03AM EDT Earnings Scheduled For August 13, 2020 Benzinga

Aug 11, 2020

07:19AM EDT ATyr Pharma Partner Kyorin Proceeds To Phase 1 Trial Of ATYR1923 In Japan RTTNews

07:05AM EDT aTyr Pharma Highlights Partner, Kyorin Pharma, Will Proceed To Phase 1 Trial Of ATYR1923 In Japan Benzinga

07:00AM EDT aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. GlobeNewswire Inc